BPC 157 dosage Calculator

• Low (0.25mg / 250mcg): Frequently applied in baseline systemic models or studies observing minor localized tissue repair in smaller test subjects.¹
• Mid (0.5mg / 500mcg): The standard median dosage in experimental literature, widely cited in protocols evaluating accelerated healing of acute muscle, tendon, or ligament injuries.²
• High (1.0mg / 1000mcg): Typically reserved for severe trauma models, post-surgical recovery simulations, or subjects with higher body mass requiring a robust systemic response.³
  

In experimental protocols, BPC-157 is most commonly administered once to twice daily. Because of its relatively short systemic half-life, researchers often split the mid (0.5mg) or high (1.0mg) experimental dosages into two equal administrations (e.g., morning and evening) to maintain consistent localized or systemic concentrations throughout the primary healing window.¹

Research literature documents several administration routes, largely dictated by the specific objective of the study:

• Subcutaneous (SubQ): The benchmark route for systemic research, including gastrointestinal healing, neuroprotection, and general inflammatory modulation.⁴
• Intramuscular (IM): Frequently utilized in localized studies targeting specific tendon, ligament, or muscle injuries to introduce the peptide adjacent to the site of trauma.²
• Oral: BPC-157 is uniquely stable in gastric juice, and oral administration is heavily documented in gut-permeability and ulcer models.⁴

BPC-157 research generally follows acute to sub-acute timelines, focusing on the rapid up-regulation of angiogenic growth factors.

• Acute Repair Models: 2 to 4 weeks is the standard timeline for observing localized tendon, ligament, or muscle healing.²
• Systemic/Gastrointestinal Models: 4 to 8 weeks for observing chronic inflammatory conditions or ulcer resolution. Literature rarely dictates continuous, long-term administration once the primary tissue repair or baseline homeostatic endpoints are achieved.³

While extensive in vitro and animal models demonstrate BPC-157’s profound angiogenic and cytoprotective properties—accelerating angiogenesis and modulating the inflammatory response—large-scale, peer-reviewed human clinical trials are currently lacking. BPC-157 is not approved by the FDA for treating injuries, ulcers, or inflammatory bowel conditions in humans. All data provided is strictly for educational context, and all compounds are restricted to Research Use Only (RUO).

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract, clinic and controlled psychiatric ward patients. Curr Med Chem. 2011;18(14):2044-2055. https://pubmed.ncbi.nlm.nih.gov/21548867/
2. Gwyer D, Vrancic M, Jelic I, et al. Gastric pentadecapeptide BPC 157 in healing of muscle and tendon injuries. Curr Cell Pharmacol. 2019;14(4):301-310. https://pubmed.ncbi.nlm.nih.gov/30915550/
3. Xue XC, Wu YJ, Gao MT, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2015;21(14):4164-4170. https://pubmed.ncbi.nlm.nih.gov/25629352/
4. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. https://pubmed.ncbi.nlm.nih.gov/27840341/